IL6 and neoplasm: A more significant increment in the serum IL‐6 and TNF‐α levels were observed in anti‐PD‐L1‐DOX‐R848‐MIP‐3α/TKNP at days 15 (198.7 ± 28.1 pg/ml and 207.8 ± 25.9 pg/ml) and 20 (196.8 ± 22.9 pg/ml and 208.9 ± 25.9 pg/ml), respectively, which is accredited to the PD‐L1‐mediated tumor specificity and ROS‐responsive release of therapeutic cargos.